六细胞因子(cytokineCK).ppt

,Click to edit Master title style,Click to edit Master text styles,Second Level,Third Level,Fourth Level,Fifth Level,2001,免疫学信息网,Click to edit Master title style,Click to edit Master text styles,Second Level,Third Level,Fourth Level,Fifth Level,Click to edit Master title style,Click to edit Master text styles,Second Level,Third Level,Fourth Level,Fifth Level,Click to edit Master title style,Click to edit Master text styles,Second Level,Third Level,Fourth Level,Fifth Level,Click to edit Master title style,Click to edit Master text styles,Second Level,Third Level,Fourth Level,Fifth Level,Click to edit Master title style,Click to edit Master text styles,Second Level,Third Level,Fourth Level,Fifth Level,Click to edit Master title style,Click to edit Master text styles,Second Level,Third Level,Fourth Level,Fifth Level,Click to edit Master title style,Click to edit Master text styles,Second Level,Third Level,Fourth Level,Fifth Level,Click to edit Master title style,Click to edit Master text styles,Second Level,Third Level,Fourth Level,Fifth Level,Click to edit Master title style,Click to edit Master text styles,Second Level,Third Level,Fourth Level,Fifth Level,Click to edit Master title style,Click to edit Master text styles,Second Level,Third Level,Fourth Level,Fifth Level,Click to edit Master title style,Click to edit Master text styles,Second Level,Third Level,Fourth Level,Fifth Level,六细胞因子（cytokineCK）,第一节,CK,的共同特点,多为小分子多肽；,在较低浓度下即有生物学活性；,通过结合细胞表面高亲和力受体发挥生物学效应；,以自分泌、旁分泌或内分泌形式发挥作用；,5.,白细胞介素,(,interleukin,IL,):,IL-1IL-35,干扰素,(,interferon,IFN,):,IFN,a,/IFN/IFN,肿瘤坏死因子,(,tumor necrosis factor,TNF,),超家族,:,TNF,a,/(LT,a,)/CD40L/FasL,集落刺激因子,(,colony-stimulating factor,CSF,):,G/M-CSF/EPO/TPO,趋化因子,(,chemokine,):,CC/CXC/C/CXXXC,生长因子,(,growth factor,GF,):,EGF/VEGF/FGF/TGF,b,第二节,CK,的分类,第三节,CK,的生物学活性,1.,调节固有免疫应答,;2.,调节适应性免疫应答,3.,刺激造血,4.,促进凋亡，直接杀伤靶细胞,在肿瘤坏死因子超家族中，有几种,CK,可直接杀伤靶细胞,(TNF,a,LT,a,),或诱导细胞凋亡,(,膜型或可溶型,FasL);,5.,促进创伤的修复,EGF(,促进皮肤溃疡和创口的愈合,)/VEGF(,促进血管和淋巴管生成,)/FGF(,促进慢性软组织溃疡的愈合,)/TGF,b,(,刺激成纤维细胞和成骨细胞促进损伤组织的修复,),CK,的生物学活性,第四节,CK,受体,第五节,CK,与临床,名称,FDA,批准年份,治疗的疾病,重组,IFN-,a,1986,人毛细胞白血病、卡波氏肉瘤、慢性髓性白血病、滤泡性非霍奇金淋巴瘤、,T,淋巴瘤皮肤转移瘤、肾细胞癌、黑色素瘤、尖锐湿疣、丙肝、乙肝,重组,EPO,1989,慢性肾衰引起的重度贫血、,抗,AIDS,药物,AZT,引起的严重贫血,重组,IFN-,g,1990,慢性肉芽肿病,重组,G/GM-CSF,1991,肿瘤化疗后白细胞减少,重组,IFN-,b,1993,多发性硬化,IL-11,1993,化疗引起的血小板减少,TNF,嵌合抗体,1997,溃疡性结肠炎、类风湿性关节炎,重组,IL-1R,拮抗蛋白,1998,类风湿性关节炎,hTNF mAb,2001,类风湿性关节炎、克隆氏病,TNFR-Ig,融合蛋白,2002,类风湿性关节炎,抗,EGFR,嵌合抗体,2004,转移性结肠直肠癌、头颈部肿瘤,抗,VEGF,人源抗体,2006,年龄相关的黄斑变性,谢谢！,